SCHEMBL30062004

SCHEMBL30062004

CC(C)(C)OC(=O)N1CCN(c2cc(F)c3c(c2F)CCC(NC(=O)OCc2ccccc2)C3)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
BACE1 P56817 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPK1 P28482 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
ALDH1A1 P00352 2/20 0.42
POLB P06746 1/20 0.42
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
CTSK P43235 1/20 0.42
P2RX7 Q99572 1/20 0.42
NTSR1 P30989 1/20 0.42
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
RORC P51449 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20722620 1.00 ACHE (0.47) ACHECA1CA2BACE1L3MBTL1
SCHEMBL21685901 0.92 CA1 (0.45) ACHECA1CA2BACE1L3MBTL1
SCHEMBL20722846 0.90 CA1 (0.48) ACHECA1CA2MEN1KMT2A
SCHEMBL30968530 0.88 CA1 (0.45) ACHECA1CA2L3MBTL1MEN1
SCHEMBL28576430 0.86 CA1 (0.48) ACHECA1CA2BACE1L3MBTL1
SCHEMBL20722621 0.86 CA1 (0.48) ACHECA1CA2BACE1L3MBTL1
SCHEMBL20722765 0.83 BACE1 (0.47) ACHECA1CA2BACE1L3MBTL1
SCHEMBL28565689 0.83 BACE1 (0.47) ACHECA1CA2BACE1L3MBTL1
SCHEMBL20722459 0.81 CA1 (0.47) ACHECA1CA2MEN1KMT2A
SCHEMBL30968474 0.80 CA1 (0.44) ACHECA1CA2L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2024-12-10 US disclosed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 ACHE 1811/4885CA1 1259/4885CA2 2429/4885
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 ACHE 1811/4885CA1 1259/4885CA2 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.